# Safe Accelerated Venetoclax Escalation in CLL

> **NCT04843904** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 40 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Obinutuzumab
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04843904
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-14
- **Primary completion:** 2025-06-02
- **Final completion:** 2030-06-02
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04843904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04843904, "Safe Accelerated Venetoclax Escalation in CLL". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT04843904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*